Mechanisms of vascular hyporesponsiveness in septic shock

Current Vascular Pharmacology

Volumn 11, Issue 2, 2013, Pages 139-149

  Kimmoun, Antoine ^a,b   Ducrocq, Nicolas ^a,b   Levy, Bruno ^a,b  

^a CHU NANCY BRABOIS   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Catecholamine; Nitric oxide; Potassium channels; Septic shock; Vasopressor

Indexed keywords

ACTIVATED PROTEIN C; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADRENERGIC RECEPTOR; ARGININE; CANAVANINE; CATECHOLAMINE; CAVEOLIN 1; CORTICOSTEROID; CYCLOOXYGENASE 2; DOBUTAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FREE RADICAL; GLIBENCLAMIDE; HYDROCORTISONE; HYDROGEN PEROXIDE; INSULIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NITRIC OXIDE; NORADRENALIN; PEROXYNITRITE; PLACEBO; PROSTACYCLIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; TERLIPRESSIN; VASOPRESSIN; XANTHINE OXIDASE; POTASSIUM CHANNEL; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ACIDOSIS; ARTERIAL PRESSURE; ARTICLE; CRITICAL ILLNESS; DESENSITIZATION; HUMAN; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPOTENSION; HYPOXIA; LOW DRUG DOSE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; MEDICAL LITERATURE; NONHUMAN; OXIDATION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; VASCULAR DISEASE; VASCULAR HYPORESPONSIVENESS; VASCULAR SMOOTH MUSCLE; VASODILATATION; VASOPLEGIA; ANIMAL; HISTORY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CATECHOLAMINES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NITRIC OXIDE; POTASSIUM CHANNELS; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84875330082     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113805290245     Document Type: Article

References (90)

1. Brun-Buisson C, Meshaka P, Pinton P, Vallet B, Group ES: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30:580-588.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7):1303-1310.
3. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008; 36:296-327.
4. Matsuda N, Hattori Y. Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res 2007; 43:117-137.
5. Umans JG, Wylam ME, Samsel RW, Edwards J, Schumacker PT. Effects of endotoxin in vivo on endothelial and smooth-muscle function in rabbit and rat aorta. Am Rev Respir Dis 1993; 148:1638-1645.
6. Levy B, Collin S, Sennoun N, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med 2010; 36:2019-2029.
7. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine--mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 2000; 68:293-303.
8. Bernardin G, Pradier C, Tiger F, Deloffre P, Mattei M. Blood pressure and arterial lactate level are early indicators of short-term survival in human septic shock. Intensive Care Med 1996;17-25.
9. Abid O, Akca S, Haji-Michael P, Vincent JL. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med 2000; 28:947-949.
10. Benchekroune S, Karpati PC, Berton C, et al. Diastolic arterial blood pressure: a reliable early predictor of survival in human septic shock. J Trauma 2008; 64:1188-1195.
11. Benedict CR, Rose JA. Arterial norepinephrine changes in patients with septic shock. Circ Shock 1992; 38:165-172.
12. Alvarez S, Boveris A. Mitochondrial nitric oxide metabolism in rat muscle during endotoxemia. Free Radic Biol Med 2004; 37:1472-1478.
13. Muniyappa R, Xu R, Ram JL, Sowers JR. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2000; 278: H1762-1768.
14. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990; 259:H1038-1043.
15. Boyle WA, 3rd, Parvathaneni LS, Bourlier V, Sauter C, Laubach VE, Cobb JP. iNOS gene expression modulates microvascular responsiveness in endotoxin-challenged mice. Circ Res 2000; 87:E18-24.
16. Walker TA, Curtis SE, King-VanVlack CE, Chapler CK, Vallet B, Cain SM. Effects of nitric oxide synthase inhibition on regional hemodynamics and oxygen transport in endotoxic dogs. Shock 1995; 4:415-420.
17. Cobb JP, Natanson C, Quezado ZM, et al. Differential hemodynamic effects of L-NMMA in endotoxemic and normal dogs. Am J Physiol 1995; 268:H1634-1642.
18. Cohen RI, Shapir Y, Chen L, Scharf SM. Right ventricular overload causes the decrease in cardiac output after nitric oxide synthesis inhibition in endotoxemia. Crit Care Med 1998; 26:738-747.
19. Herbertson MJ, Werner HA, Walley KR. Nitric oxide synthase inhibition partially prevents decreased LV contractility during endotoxemia. Am J Physiol 1996; 270:H1979-1984.
20. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 2000; 161:1781-1785.
21. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30.
22. Levy B, Valtier M, de Chillou C, Bollaert PE, Cane D, Mallie JP. Beneficial effects of L-canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphates during endotoxic shock in rats. Shock 1999; 11:98-103.
23. Cauwels A. Nitric oxide in shock. Kidney Int 2007; 72:557-565.
24. Cauwels A, Buys ES, Thoonen R, Geary L, Delanghe J, Shiva S, Brouckaert P. Nitrite protects against morbidity and mortality associated with TNF-or LPS-induced shock in a soluble guanylate cyclase-dependent manner. J Exp Med 2009; 206:2915-2924.
25. Vane J, Corin RE. Prostacyclin: a vascular mediator. Eur J Vasc Endovasc Surg 2003; 26:571-578.
26. Wang P, Zhou M, Cioffi WG, Bland KI, Ba ZF, Chaudry IH. Is prostacyclin responsible for producing the hyperdynamic response during early sepsis? Crit Care Med 2000; 28:1534-1539.
27. Schildknecht S, Bachschmid M, Baumann A, Ullrich V. COX-2 inhibitors selectively block prostacyclin synthesis in endotoxinexposed vascular smooth muscle cells. FASEB J 2004; 18:757-759.
28. Hocherl K, Dreher F, Kurtz A, Bucher M. Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension 2002; 40:947-953.
29. Hocherl K, Schmidt C, Kurt B, Bucher M. Activation of the PGI(2)/IP system contributes to the development of circulatory failure in a rat model of endotoxic shock. Hypertension 2008; 52:330-335.
30. Staehr M, Madsen K, Vanhoutte PM, Hansen PB, Jensen BL. Disruption of COX-2 and eNOS does not confer protection from cardiovascular failure in lipopolysaccharide-treated conscious mice and isolated vascular rings. Am J Physiol Regul Integr Comp Physiol 2011; 301:R412-420.
31. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912-918.
32. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87:315-424.
33. Szabo C, Salzman AL, Ischiropoulos H. Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett 1995; 363:235-238.
34. Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 2008; 173:2-13.
35. Yard AC, Kadowitz PJ. Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. Eur J Pharmacol 1972; 20:1-9.
36. Macarthur H, Westfall TC, Riley DP, Misko TP, Salvemini D. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc Natl Acad Sci USA 2000; 97:9753-9758.
37. Biesalski HK, McGregor GP. Antioxidant therapy in critical care--is the microcirculation the primary target? Crit Care Med 2007; 35:S577-583.
38. Pleiner J, Mittermayer F, Schaller G, MacAllister RJ, Wolzt M. High doses of vitamin C reverse Escherichia coli endotoxininduced hyporeactivity to acetylcholine in the human forearm. Circulation 2002; 106:1460-1464.
39. Buckley JF, Singer M, Clapp LH. Role of KATP channels in sepsis. Cardiovasc Res 2006; 72:220-230.
40. Collin S, Sennoun N, Dron AG, et al. Vascular ATP-sensitive potassium channels are over-expressed and partially regulated by nitric oxide in experimental septic shock. Intensive Care Med 2011; 37:861-869.
41. Morelli A, Lange M, Ertmer C, et al. Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary performance, and global oxygen transport. Shock 2007; 28:530-535.
42. Warrillow S, Egi M, Bellomo R. Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 2006; 34: 980-985.
43. Cauwels A, Brouckaert P. Critical role for small and large conductance calcium-dependent potassium channels in endotoxemia and TNF toxicity. Shock 2008; 29:577-582.
44. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937-1949.
45. Grunfeld JP, Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension 1987; 10:608-618.
46. Williamson PM, Kohlhagen JL, Mangos GJ, Whitworth JA, Kelly JJ. Acute effects of hydrocortisone on plasma nitrate/nitrite activity and forearm vasodilator responsiveness in normal human subjects. Clin Exp Pharmacol Physiol 2005; 32:162-166.
47. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J 1997; 16:4698-4707.
48. Prigent H, Maxime V, Annane D. Clinical review: corticotherapy in sepsis. Crit Care 2004; 8:122-129.
49. Leach M, Hamilton LC, Olbrich A, Wray GM, Thiemermann C. Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone. Br J Pharmacol 1998; 124: 586-592.
50. Steiner A, Locher R, Sachinidis A, Vetter W. Cortisol-stimulated phosphoinositide metabolism in vascular smooth muscle cells: a role for glucocorticoids in blood pressure control? J Hypertens Suppl 1989; 7:S140-141.
51. Wu LL, Tang C, Liu MS. Hyper-and hypocardiodynamic states are associated with externalization and internalization, respectively, of alpha-adrenergic receptors in rat heart during sepsis. Shock 1997; 7:318-323.
52. Baker CH, Sutton ET, Price JM, Ortiz-Tweed M, Nessellroth S. Attenuation of arteriolar alpha 2-adrenoceptor sensitivity during endotoxemia. Am J Physiol 1994; 267:H2171-2178.
53. Price SA, Spain DA, Wilson MA, Harris PD, Garrison RN. Subacute sepsis impairs vascular smooth muscle contractile machinery and alters vasoconstrictor and dilator mechanisms. J Surg Res 1999; 83:75-80.
54. Hwang TL, Lau YT, Huang SF, Chen MF, Liu MS. Changes of alpha 1-adrenergic receptors in human liver during intraabdominal sepsis. Hepatology 1994; 20:638-642.
55. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S. Modification of alpha1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 2002; 30:894-899.
56. de Montmollin E, Aboab J, Mansart A, Annane D. Bench-tobedside review: Beta-adrenergic modulation in sepsis. Crit Care 2009; 13:230.
57. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461.
58. Pacheco ME, Beltran A, Redondo J, Manso AM, Alonso MJ, Salaices M. High glucose enhances inducible nitric oxide synthase expression. Role of protein kinase C-betaII. Eur J Pharmacol 2006; 538:115-123.
59. Ellger B, Richir MC, van Leeuwen PA, et al. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 2008; 149:3148-3157.
60. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297.
61. Annane D, Cariou A, Maxime V, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303:341-348.
62. Stoclet JC, Martinez MC, Ohlmann P, et al. Induction of nitric oxide synthase and dual effects of nitric oxide and cyclooxygenase products in regulation of arterial contraction in human septic shock. Circulation 1999; 100:107-112.
63. Angus JA, Wright CE. Techniques to study the pharmacodynamics of isolated large and small blood vessels. J Pharmacol Toxicol Methods 2000; 44:395-407.
64. Spronk PE, Ince C, Gardien MJ, Mathura KR, Oudemans-van Straaten HM, Zandstra DF. Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet 2002; 360:1395-1396.
65. Havel C, Arrich J, Losert H, Gamper G, Mullner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2011;CD003709.
66. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779-789.
67. Levy B, Gibot S, Franck P, Cravoisy A, Bollaert PE. Relation between muscle Na+K+ ATPase activity and raised lactate concentrations in septic shock: a prospective study. Lancet 2005; 365:871-875.
68. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370:676-684.
69. LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000; 28:2729-2732.
70. Breslow MJ, Ligier B. Hyperadrenergic states. Crit Care Med 1991; 19:1566-1579.
71. Katsaragakis S, Kapralou A, Theodorou D, et al. Refractory septic shock: efficacy and safety of very high doses of norepinephrine. Methods Find Exp Clin Pharmacol 2006; 28:307-313.
72. Ataman K, Jehmlich M, Kock S, et al. Short-term cardiovascular effects of plasmapheresis in norepinephrine-refractory septic shock. Intensive Care Med 2002; 28:1164-1167.
73. Honore PM, Matson JR. Short-term high-volume hemofiltration in sepsis: perhaps the right way is to start with. Crit Care Med 2002; 30:1673-1674.
74. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001; 29:1860-1867.
75. Lange M, Ertmer C, Westphal M. Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med 2008; 34(5):821-832.
76. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125.
77. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30:497-500.
78. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887.
79. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res 1990; 16:307-314.
80. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 2009; 13:R130.
81. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
82. Bilbault P, Lavaux T, Launoy A, et al. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med 2007; 35:69-75.
83. Esmon CT. The endothelial protein C receptor. Curr Opin Hematol 2006; 13:382-385.
84. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276:11199-11203.
85. Sennoun N, Meziani F, Dessebe O, et al. Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 2009; 37:246-255.
86. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
87. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
88. Kilger E, Weis F, Briegel J, et al. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 2003; 31:1068-1074.
89. Gibot S, Massin F, Alauzet C, et al. Effects of the TREM-1 pathway modulation during mesenteric ischemia-reperfusion in rats. Crit Care Med 2008; 36:504-510.
90. Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative G. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.